bosentan anhydrous has been researched along with Kahler Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagnato, A; Bonalumi, A; Cassaro, A; Cassatella, MA; Giacomazzi, A; Gottardi, M; Mosna, F; Rigo, A; Rosanò, L; Russignan, A; Salvadori, U; Scupoli, MT; Spina, C; Tamassia, N; Tecchio, C; Tinelli, M; Vinante, F; Zamò, A; Zanatta, L | 1 |
| Schäfer, J; Theile, D; Weiss, J | 1 |
2 other study(ies) available for bosentan anhydrous and Kahler Disease
| Article | Year |
|---|---|
Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Autocrine Communication; Bortezomib; Bosentan; Cell Proliferation; Cell Survival; DNA Methylation; DNA, Neoplasm; Drug Synergism; Endothelin A Receptor Antagonists; Endothelin-1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Plasma Cells; Promoter Regions, Genetic; Receptor, Endothelin A; Sulfonamides; Tumor Cells, Cultured | 2017 |
Bosentan enhances in vitro bortezomib's anti-proliferative potency against multiple myeloma by mechanisms going beyond endothelin receptor blockade.
Topics: Bortezomib; Bosentan; Endothelin-1; Humans; Multiple Myeloma; Receptor, Endothelin A | 2019 |